To compare Which is more useful in the treatment of acute bronchial asthma in childrens of 6-12 years when comparing between Magnesium Sulfate with salbutamol and salbutamol alone as the treatment

Effectiveness and Safety Of Add On- Nebulized MgSO4 with salbutamol and Salbutamol Alone in Bronchial Asthma Management in Children of 6-12 Years. A Randomized controlled Trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/099967

Enrollment

126

Registered

2025-12-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00-J99- Diseases of the respiratory system

Interventions

Intervention1: Magnesium Sulfate with Salbutamol: Magnesium Sulfate of dose 100mg with 0.5 ml of salbutamol is used in the form of nebulization for 4 times a day then the frequency of nebulization is

Eligibility

Inclusion criteria

Inclusion criteria: Children between 6 years and 12 years of age with acute bronchial asthma

Exclusion criteria

Exclusion criteria: Children below 6 years of age Cardiac diseases such as congenital heart diseases Preterm birth or history of mechanical ventilation in neonatal period History of pneumonia

Design outcomes

Primary

Measure	Time frame
To evaluate the mean duration of hospital stay and change in clinical severity score parameters (respiratory rate ,o2 saturation , wheezing , retraction, general condition)Timepoint: Assess pre treatment severity before 1st nebulization. Detect early response after 1st dose(after 6 hours of 1st dose), Evaluate ongoing improvement (on day 2,3,4) and final clinical outcome based on reduction of clinical severity score (on day 5)	—

Measure

Time frame

To evaluate the mean duration of hospital stay and change in clinical severity score parameters (respiratory rate ,o2 saturation , wheezing , retraction, general condition)Timepoint: Assess pre treatment severity before 1st nebulization. Detect early response after 1st dose(after 6 hours of 1st dose), Evaluate ongoing improvement (on day 2,3,4) and final clinical outcome based on reduction of clinical severity score (on day 5)

—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Chandru bhaskar

Aarupadai veedu medical college and hospital

chandru14885@gmail.com9791783036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026